- Novocure (NASDAQ:NVCR) has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are electric fields that disrupt cancer cell division.
- Research to be conducted will study Tumor Treating Fields in combination with various pharmacological agents, to identify new indications for use and understand its effects on cancer and to fuel development of new treatment strategies.
- Also, the company posted a solid Q3 beat, with revenue of $132.66M, +44.1% Y/Y, and net income was $9.3M, +389.5% Y/Y.
- Q3 non-GAAP EBITDA was $37.3M, an increase of 85% vs. prior year.
- This improvement was driven by net revenue growth, coupled with disciplined management of expenses.
- Anticipated milestones: Data from phase 2 pilot HEPANOVA trial in advanced liver cancer in Q1 2021.
- Data from phase 2 pilot EF-31 trial in gastric cancer in 2021.
- Interim analysis of phase 3 LUNAR trial, PANOVA-3 trial and INNOVATE-3 trial in 2021.
- Data from phase 3 METIS trial and from phase 2 pilot EF-33 trial in 2022.
- Final data from phase 3 LUNAR trial in NSCLC, from phase 3 PANOVA-3 trial in pancreatic cancer and phase 3 INNOVATE-3 trial in recurrent ovarian cancer in 2023.
- https://seekingalpha.com/news/3628021-novocure-to-conduct-research-in-tumor-treating-fields-posts-strong-q3-beating-consensus
Thursday, October 29, 2020
Novocure to conduct research in Tumor Treating Fields; strong Q3 beat
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.